No Data
Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed With Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)
Arch Biopartners Begins Patient Dosing in Canada in Phase II Trial For LSALT Peptide
Units for Debt Settlement
Arch Biopartners Receives Approval From Alberta Health Services to Proceed With Phase II Trial
Arch Biopartners' Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins
Arch Biopartners Closes Non-Brokered Private Placement
